Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

23-03-2023

Liz Hockley

Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

Pavel Kapysh / Shutterstock.com

Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.


Amarin, patent infringement, generic, Hikma, heart, drug, Vascepa, US Food and Drug Administration, patents, skinny labels

LSIPR